(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

INGELHEIM, Germany and PLEASANTON, Calif., March 11, 2025 /PRNewswire/ -- Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer’s One Medicine Platform, ...

Cognizant, as the prime system integrator, began the Boehringer Ingelheim project by codeveloping a program roadmap, agile methodology, and implementation workflow. The overall scope of the project ...

Over-the-counter (OTC) inhalers are not approved for treating chronic obstructive pulmonary disease (COPD). Aside from the fact that they are ineffective for COPD, these inhalers can pose risks ...

The demand notice was issued after the bank’s GST filings were audited annually. Officials found discrepancies in the filings that resulted in the tax claim.

What Is Chronic Obstructive Pulmonary Disease (COPD)? Chronic obstructive pulmonary disease (COPD), an irreversible form of lung disease, is treated with prescription drugs, lifestyle changes, ...

Learn what you can do to reduce the risk of wildfires and mitigate their impact. Special Needs Assistance for Seniors provides financial assistance to eligible seniors with low-income toward the cost ...